Total Utang marang Modal Veru Pharma (VERU)

Veru - logo grafis emiten VERU

Veru Inc. (VERU) has redirected its capacities toward weight loss testing, relying on partnerships and the development of proprietary research while completely abandoning mergers. Business revenues are based on the sale of feminine hygiene products and the creation of prostate and breast tumor therapies. Serving as the primary valuation tool, this price chart with the 0.09 indicator confirms a steady cash flow generated by patent protection and perpetual demand for oncological treatment.

verupharma.com (VERU): Rasio Utang marang Ekuitas saka 04.07.2022 nganti 29.10.2026

Rincian metrik lan analitis perusahaan Veru Corporation (VERU)

- rega saham lan konsensus proyeksi valuasi:
Rega saham Veru|VERU - Target konsensus
- rincian kapitalisasi pasar:
Kapitalisasi pasar Veru|VERU - Nilai Perusahaan
- indikator kapitalisasi buku:
Aset Bersih saben Siji Saham Veru|VERU - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku verupharma.com|VERU - Gunggung Aset Perusahaan
- rincian utang lan likuiditas:
Total Utang marang Modal Veru Inc.|VERU - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Veru Inc.|VERU - Kewajiban utang agregat|Utang marang nilai buku Veru|VERU - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Veru|Indikator likuiditas cepet verupharma.com
- data bathi resik lan rasio valuasi:
VERU - Bathi resik
Pambiji fundamental perusahaan:Veru
Produk dadi Veru Inc.

Maintaining liquidity is critical for Veru Inc. (VERU), as its success depends on funding clinical trials for cancer and obesity therapies. By analyzing the debt-to-equity ratio, an investor assesses the level of leverage within the capital structure to determine the business's ability to withstand market cycles without risking asset loss due to excessive debt burden.

Analisis pesaing Veru Inc.

ONC (BeiGene) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas Halozyme Therapeutics, Inc. (HALO)|Total Utang marang Modal RVMD|Total Utang marang Modal Ascentage Pharma Corp (AAPG)|Utang marang Ekuitas CG Oncology, Inc. CGON|URGN: Rasio Utang marang Ekuitas|Bicara Therapeutics - Total Utang marang Modal|Personalis Inc (PSNL) - Rasio Total Utang marang Ekuitas|ERAS: Total Utang marang Modal|Utang marang Modal Delcath Corp (DCTH)|Utang marang Ekuitas Y-mAbs Therapeutics|AURA: Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas CADL (Candel Therapeutics)|ARAY (Accuray Inc) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal SLS (SELLAS Life Sciences Group)|ACTU - Rasio Total Utang marang Ekuitas|CTOR: Rasio Total Utang marang Ekuitas|HURA - Total Utang marang Modal|Protara Therapeutics, Inc. (TARA) - Utang marang Ekuitas|Fate Therapeutics Inc - Rasio Kabeh Utang marang Dana Pribadi|WHWK (Aadi Bioscience, Inc.) - Total Utang marang Modal|Utang marang Modal TScan TCRX|Rasio Total Utang marang Ekuitas CSBR (Champions Oncology)|Utang marang Ekuitas XBIT (xbiotech.com)|Total Utang marang Modal CVM (CEL-SCI)|OS Therapies Inc. (OSTX) - Utang marang Modal|RADX - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi ARTV (Artiva Biotherapeutics, Inc.)|ANL (adlainortye.com) - Rasio Total Utang marang Ekuitas|tempesttx.com (TPST) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas XLO|RENB: Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal MURA|Koefisien Total Utang marang Modal kairospharma.com|Utang marang Ekuitas OnKure Therapeutics OKUR|GDTC: Rasio Utang marang Ekuitas|Curis Corp - Total Utang marang Modal|Apollomics, Inc. (APLM) - Rasio Total Utang marang Ekuitas|THAR (Tharimmune Corp) - Rasio Total Utang marang Ekuitas|ADVB - Koefisien Total Utang marang Modal|Rasio Total Utang marang Ekuitas GNPX|Utang marang Ekuitas CLDI|Total Utang marang Modal SBFM|XBIO - Utang marang Modal|Utang marang Ekuitas Salarius SLRX|Rasio Kabeh Utang marang Dana Pribadi PPBT|AONC: Rasio Total Utang marang Ekuitas|BGNE - Total Utang marang Modal|CKPT: Total Utang marang Modal|Rasio Total Utang marang Ekuitas elevationoncology.com|ICAD (iCAD Inc.) - Total Utang marang Modal|Total Utang marang Modal Ikena|Utang marang Ekuitas Notable Labs, Ltd. (NTBL)|viracta.com - Rasio Utang marang Ekuitas|Total Utang marang Modal MOR (MorphoSys)|NAYA - Rasio Total Utang marang Ekuitas|Ascentage Pharma Group Ltd - Total Utang marang Modal